Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,132.19
(
-0.58%
)
US TECH 100
26,266.40
(
-1.14%
)
Dow Jones
49,202.39
(
-0.22%
)
Brent Oil
104.16
(
2.00%
)
Bitcoin
76,131.00
(
-1.60%
)
News Focus
News Focus
Post# of 257457
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122896
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 228077

Monday, 01/13/2020 5:43:57 PM

Monday, January 13, 2020 5:43:57 PM

Post# of 257457
ENTA—Re: hMPV

This excerpt from ENTA’s 1/9/20 PR (#msg-153206240) is being discussed on the JPM webcast:

We are also introducing today our newest program, which is for treatment of hMPV, a pathogen identified in 2001 that causes upper and lower respiratory tract infections in young children and the elderly, as well as COPD, asthma, and immunocompromised patients.

“hMPV” is human metapneumovirus, which is similar to RSV and has no approved vaccines or treatments.

ENTA's hMPV program is in the lead-optimization stage.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today